Chinese pharmaceutical firm launches traditional medicine in Kenya

NAIROBI, Nov. 24 (Xinhua) — A Chinese pharmaceutical company on Tuesday launched traditional medicine that is to be used to boost immunity, treat and manage viral pneumonia.

Jiangyin Tianjiang Pharmaceutical Company, which will be operating under a local agent, XRP Medical Kenya Limited, introduced Healthouself Formula 3 and Healthouself Formula 5 combinations of herbal medicines in the country.

“The medicine will be used to prevent and strengthen immunity and treatment for types of severe acute respiratory infections,” Edgar Ngugi, general manager, XRP Medical Kenya said during the launch in Nairobi.

Ngugi said that the combinations will be used to prevent and strengthen immunity and treatment for severe acute respiratory infections.

He said that Kenya’s drug regulatory authority, Pharmacy and Poison Board (PPB) has approved and certified the two herbal products for sale in the country.

“The ingredients found in the two herbal medicines have been tried and tested in China as a complementary prevention alongside other treatment options to manage respiratory diseases,” said Ngugi.

He said the products were used alongside other conventional medicine during the peak of COVID-19 outbreak in Wuhan to treat acute respiratory infections by boosting patient’s immunity.

“The products have undergone rigorous scrutiny exercise by relevant government bodies and the World Health Organization (WHO) has approved for human consumption,” said Ngugi.

He clarified that the herbal products should not be prescribed for children under three years and pregnant women adding that their dosage is being worked on and will be available soon in the market.

“As an institution, we believe prevention is better than cure and so we aspire to introduce more and more products to awaken the giants within us. Our bodies are naturally wired to fight some of these ailments if we take necessary action and boost our immunity accordingly,” said Ngugi.

Source Article

Read more

111 to be the Omni-channel Drug Commercialization Partner of Xiangxu Pharmaceutical for Traditional Chinese Medicine

SHANGHAI, Oct. 15, 2020 /PRNewswire/ — On September 24, 111, Inc. (the “Company” or “111″) and Guangzhou Xiangxue Pharmaceutical Co., Ltd. (“Xiangxue Pharmaceutical”) officially signed a strategic partnership agreement (the “Agreement”) to deepen collaboration to further develop the “Internet + Medicine” model for China’s traditional Chinese medicine industry.

Per the Agreement, 111 will become an omni-channel commercialization partner of Xiangxue Pharmaceutical. Through the integration of Smart Supply Chain, digital marketing, data capabilities, and cloud services, Xiangxue Pharmaceutical will be able to promote its abundant traditional Chinese medicine products into new markets through online and offline platforms, as well as expanding into existing markets.

As the pioneer in “Internet + Medicine” platform, 111 has built China’s largest digital healthcare platform that combines both online and offline channels covering 280,000 pharmacies nationwide. In the often underserved tier 3-6 cities, 111 covers over 63% of retail pharmacies. The Agreement aims to combine the strength of 111′s omni-channel drug commercialization platform and Xiangxue Pharmaceutical’s expansive portfolio of products to drive the growth of traditional Chinese medicine. Both companies are excited to embark on this symbiotic partnership that aims further strengthen 111′s capabilities of connecting pharmaceutical companies with patients in need of their medicine.

Mr. ZHU Pengcheng, Co-COO of 111, commented that he has full confidence in this mutually beneficial partnership that leverages the expertise of both companies to service and promote the traditional Chinese medicine industry by combining 111′s leading digital healthcare platform and Xiangxue Pharmaceutical’s innovative product line. The two parties will collaborate in big data application, digital marketing of traditional Chinese medicine, brand building, and patient health management to optimize operations and better serve patients’ needs.

Mr. TAN Guanghua, General Manager of the Marketing Center of Xiangxue Pharmaceutical, commented that 111, as China’s leading digital healthcare platform, has tremendous competitive advantages in its technology-enabled Smart Supply Chain, omni-channel drug commercialization capabilities, and smart technology and integrated online-offline infrastructure that leverages the latest in AI, cloud-based solutions, and big data. The Agreement combines the expertise of both companies and he has full confidence that the strategic partnership will be a success in achieving significant annual sales growth for Xiangxue Pharmaceutical.

About Xiangxue Pharmaceutical

Xiangxue Pharmaceutical is specialized in the health industry, covering fields such as traditional Chinese medicine decoction pieces, Chinese patent medicine, functional healthcare products, biomedical engineering, and life science research. It has built large GAP medicinal materials planting bases and GMP production bases, building an integrated industrial chain that includes traditional Chinese medicine resources development, new drug R&D and production, advanced manufacturing of traditional Chinese medicine, and modern logistics and distribution. The company has become a leading traditional Chinese medicine modernization company with proprietary intellectual property rights, its brands and self-dependent innovation ability.

About 111, Inc.

111, Inc. (NASDAQ: YI) (“111” or the “Company”) is a leading digital healthcare platform committed to digitally connecting patients with healthcare products and services in China. The Company provides consumers with better access to pharmaceutical products and healthcare services directly through its online retail pharmacy,

Read more